Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s):  CSCI

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:CSCI - Post by User

Post by prophetoffactzon Sep 13, 2024 8:41am
84 Views
Post# 36221889

A research and development engine

A research and development engineAccording to oats Gilles appears to have said that AEZS had cash and "some strategic people in Germany that were very proficient and would hire them if he could." Ronnie Miller has said that the company is now positioned to bring transformative products to market. 

The company needed a research and development engine to explore, prioritize, and develop its potentially vast potential. It will be interesting to see what emerges over the next two years and beyond. 


Ronald W. Miller, Chair of the Company:

“With the successful completion of this merger, we are now optimized to bring value-driving, transformational products to the market.” June 2024
<< Previous
Bullboard Posts
Next >>